CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.
Sponsor: Emergent BioSolutions
Terminated
Portfolio consolidation.
Listed as NCT00893516, this PHASE2 trial focuses on T-cell Lymphoma and remains terminated or withdrawn. Sponsored by Emergent BioSolutions, it has been updated 13 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2023 — May 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Nov 2023 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Terminated PHASE2
-
May 2022 — Jun 2022 [monthly]
Terminated PHASE2
-
Dec 2021 — May 2022 [monthly]
Terminated PHASE2
-
May 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — May 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emergent BioSolutions
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.